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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not a gluten-
free diet is effective in decreasing symptoms for irritable bowel syndrome (IBS). 
Study Design: Systemic review of three randomized, double-blind, placebo-controlled trials 
published between 2010-2016, all in the English language. 
Data Sources: Data sources obtained for this review were studies published in peer reviewed 
journals found using PubMed Database and were selected based on outcomes measured and 
relevance to the objective.  
Outcomes Measured: The outcomes measured were based on reduction in abdominal symptoms 
in IBS patients. Outcomes were measured by a series of 10 cm Visual Analog Scale (VAS). The 
VAS monitored symptoms with 0 representing no symptoms and 10 indicating severe clinical 
symptoms. Symptoms observed included abdominal pain, bloating, satisfaction with stool 
consistency, and overall well-being. Patients completed a questionnaire on primary outcomes 
and symptoms. Significance of outcomes were determined using p-value, relative benefit 
increase, absolute benefit increase, and numbers needed to treat. 
Results: All three studies showed a significant decrease in abdominal symptoms in IBS patients 
following a gluten-free diet. Biesiekierski et al. found a statistically significant decrease in 
abdominal symptoms at the end of the 6 weeks study with patients who had the gluten-free diet 
compared to the gluten diet (p=0.001). Elli et al. study also found a significant difference in 
patients that had the gluten-free diet compared to the gluten diet (p= 0.001). Shahbazkhani et al. 
found reduction in abdominal symptoms with a gluten-free diet (p< 0.001). 
Conclusions: The randomized controlled trials discussed in this review suggest that a gluten-free 
diet is effective in decreasing symptoms for IBS.  
Keywords: irritable bowel syndrome, gluten-free diet
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Introduction 
 Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal 
disorders.1,2 IBS is a chronic disorder characterized by abdominal pain with association of 
alternating bowel movements.1 It is diagnosed with the Rome III criteria which includes having 
abdominal pain with 2 of the 3 criteria: abdominal discomfort relieved with defecation, change in 
stool frequency, and change in stool appearance. There are three main subtypes of IBS including 
IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M). 
Approximately 10-15% of adults and adolescents have symptoms consistent with IBS.1 
 IBS affects around 11% of the population globally.2 IBS is important to address in 
healthcare because approximately 50% of people who experience symptoms from IBS will 
consult a healthcare provider.3 Approximately 50% of patients with IBS report their first 
symptoms before the age of 35.3 Patients over 50-years-old, often have worst quality of life.3 The 
estimated annual cost for IBS treatment is between 1.7 billion dollars and 10 billion dollars in 
direct medical costs (medications) and 20 billion dollars in indirect (absentee from work) 
medical costs in the United States.4 The exact number of healthcare visits due to IBS within the 
past few years are not known; however, it is estimated that between 10% and 70% of patients 
visit their primary care provider for IBS symptoms. IBS patients are the largest subgroup seen in 
gastroenterology clinics.2  
 The cause of IBS is not completely understood. The pathogenesis of IBS is thought to be 
from altered gastrointestinal motility, brain-gut interactions, bacterial overgrowth, and food 
sensitivity.5 The first line methods to treat IBS are reassurance, lifestyle modifications, and 
dietary modifications. Pharmacologic treatment can be used to minimize symptoms including 
polyethylene glycol or magnesium hydroxide for constipation, loperamide for diarrhea, and 
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antispasmodics.1,5,6 Other adjunct treatments for IBS include cognitive behavioral therapy with 
antidepressants like tricyclic antidepressants (TCA).5,6 
 Currently, there are several treatment options and medications that can improve the 
symptoms of IBS; however, there is not one single therapy that cures all IBS symptoms. The true 
efficacy of having a gluten-free diet is still not highly researched. It is suggested that gluten 
causes intestinal injury and/or inflammation in patients with IBS. Gluten is found in three types 
of grains including wheat, rye, and barley. Wheat has been found to be one of the most common 
factors to induce gastrointestinal symptoms such as abdominal pain. Evidence suggest that 
targeted dietary carbohydrates exclusion can provide clinical benefit to patients with IBS. 
Therefore, a gluten-free diet is an alternative for relief of symptoms of IBS. A gluten-free diet 
has shown to be effective in treatment for IBS by decreasing irritation of the intestines. This 
systematic review evaluates three randomized control trials to determine if maintaining a gluten-
free diet is effective in decreasing symptoms for IBS.  
Objective 
 The objective is this selective EBM review is to determine if a gluten-free diet is 
effective in decreasing symptoms for irritable bowel syndrome (IBS). 
Methods 
 Criteria used for selection of studies for this systemic evidence-based review are focused 
on populations, interventions, comparisons, and outcomes measured. The population studied in 
these articles were patients with IBS using the Rome III criteria (Table 1). The patients were 
greater than 16 years old without any other known gastrointestinal disease including celiac 
disease. The intervention was a gluten-free diet compared to a gluten diet. The treatment group 
received a gluten diet while the control group received a gluten-free diet. The outcomes that were 
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measured used patient-oriented evidence that matters including improvements of the overall 
symptoms of IBS such as bloating, abdominal pain, stool consistency, nausea, tiredness, and 
general well-being while on a gluten-free diet verses a non-gluten free diet. 
 Research for this systematic review was obtained from PubMed that were double-
blinded, randomized controlled trails published in peer-reviewed journals. All studies were 
published in the English language and published within the last 15 years. Key words that were 
searched in these articles were “irritable bowel syndrome” and “gluten-free diet.” The articles 
were selected based on relevance to the clinical questions and outcomes of the studies that 
mattered to the patients for this systematic review. The inclusion criteria were adults greater than 
16 years old diagnosed with IBS that fulfilled the Rome III criteria (Table 1). The exclusion 
criteria were patients who have celiac disease, wheaten allergy, inflammatory bowel disease, 
and/or with significant gastrointestinal disease (Table 1). The summary of statistics used by these 
studies analyzed the data using p-value, numbers needed to treat (NNT), relative benefit increase 
(RBI), and absolute benefit increase (ABI) (Table 2).  
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Table 1: Demographics and characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions  
Biesi-
kiersk-
i7 
(2011) 
Double- 
blind 
RCT 
39 >16 
years 
old 
-Age > 16 
years old 
-Symptoms 
of IBS 
fulfilling 
Rome III 
criteria 
-Adherence 
of the diet 
for at least 6 
weeks 
Patients with celiac 
disease, gastrointestinal 
disease, excess alcohol 
intake or intake of non-
steroidal anti-
inflammatory agents 
5 Placebo or 
gluten diet, in 
the form of 2 
bread slices 
plus one 
muffin per day 
for 6 weeks, 
both groups 
were a gluten 
free diet  
Elli8 
(2016) 
Double-
blinded 
RCT 
101 > 18 
years 
old 
-Age >18 
years old 
-Routinely 
attending 
the 
gastroenter-
ological 
clinic 
-Symptoms 
consistent 
with Rome 
III criteria 
Patients with celiac 
disease, wheaten 
allergy, inflammatory 
bowel diseases, 
psychiatric disorders, 
major abdominal 
surgery, diabetes 
mellitus, systemic 
autoimmune diseases, 
having gluten-free diet 
regimen in the past 6 
months, pregnant or 
breast-feeding women, 
or already on 
pharmacological 
therapy   
3 Gluten free 
diet, placebo or 
gluten 
ingestion  
Shahb-
azkha- 
ni9 
(2015) 
Double-
blinded 
RCT 
148 > 16 
years 
old 
-Age > 16 
years old 
-Newly 
diagnosed 
IBS based 
on Rome III 
criteria 
Patients with celiac 
disease, have tried a 
gluten free diet, on a 
gluten free diet, self-
exclusion of wheat,  
inflammatory bowel 
disease and diabetes, 
using any drugs for 
depression and/or 
anxiety, used non-
steroidal anti-
inflammatory drugs, 
with abnormal lab levels 
 
76 Placebo group 
(gluten-free 
powder) vs. 
gluten 
containing 
group for 6 
weeks, both 
groups were on 
a gluten-free 
diet 
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Outcomes Measured 
 The outcomes measured in these studies were the improvements of the overall symptoms 
of IBS while on a gluten-free diet verses a non-gluten free diet. Outcomes collected were patient-
oriented evidence that matters (POEM). Outcomes were measured using the 10 cm Visual 
Analog Scale (VAS). In all studies patients completed a questionnaire, patients were told to rank 
their symptoms on a 0 to 10 scale with 0 representing no symptoms and 10 representing the most 
severe. Biesikierski et al. measured the outcomes of improvement in symptoms of IBS including 
bloating, abdominal pain, stool consistency, nausea, and tiredness. Elli et al. measured the 
outcomes by satisfaction of patient’s health status and the severity of symptoms including 
abdominal pain, satisfaction with stool consistency, bloating, postprandial fullness and general 
well-being. Shahbazkhani et al. measured the outcomes of improvements in symptoms of IBS 
including bloating, satisfaction with stool defecation, nausea, fatigue, and overall symptoms.  
Results 
 Three randomized, double-blind trials were selected for this systemic review to determine 
the efficacy of a gluten-free diet for treatment of IBS. All three studies, Biesikierski, Elli, and 
Shahbazkhani et al. study, utilized dichotomous data based on intention-to-treat analysis. The 
analysis of measured outcomes for each study is based on the overall improvement of symptoms 
for IBS. 
 Biesikierski et al. study, used gluten-free diets as the placebo for the control group (n=15) 
verses gluten diet as the intervention groups (n=19).7 Changes in symptoms in patients with IBS 
were assessed. This study included patients greater than 16 years old, symptoms of IBS, and 
adherence of diet for at least 6 weeks. This study excluded patients with celiac disease, 
gastrointestinal disease, and excess alcohol intake. Based on the inclusion and exclusion criteria, 
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39 patients were included, and 34 patients were able to complete the study with 5 patients who 
had withdrawn from the study (Table 1). Patients that ceased the study prematurely stopped due 
to intolerable increase in abdominal symptoms. The patients that participated in the study 
received either gluten or placebo in the form of two bread slices plus one muffin per day with a 
gluten-free diet for up to 6 weeks. Food diaries from the patients were maintained in week 3 and 
week 6 of the treatment period. Adherence was measured by food supplements consumption and 
maintaining a gluten-free diet. Consumption was 95% and 96% in placebo and gluten groups, 
respectively. Patients were asked if at the end of each week if symptoms were adequately 
controlled. More patients in the gluten group reported “no” to symptoms well-controlled 
compared to the placebo group (p= 0.001) (Table 2). After week 1 therapy, changes in symptoms 
from baseline scored on the VAS were significantly different in those who had the gluten diet. 
The overall results of the study indicated that patients in the gluten group had a greater score in 
severity of pain, bloating, satisfaction with stool consistency, and tiredness. Based on the results 
in the Biesikierski et al. study, relative benefit increase (RBI) was -41.1%, absolute benefit 
increase (ABI) was -28%, and the numbers needed to treat (NNT) was -3 (Table 2). The negative 
ABI indicates that there was 28% increase of an adverse event as a result of the gluten diet. The 
negative NNT value means that for every 3 participants who had a gluten containing diet, there 
was one fewer incidence of decreased IBS symptoms than in the group of participants in the 
placebo group. 
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Table 2: Comparison and statistical significance of outcomes measured of included studies 
Study P-Value RBI ABI NNT 
Biesikierski7 0.001 -41.1% -28% -3 
Elli8 0.001 -67.2% -50.6% -1 
Shahbazkhani9 <0.001 -69.3% -58.1% -1 
 
 In the Elli et al. study, 140 patients were enrolled, and 134 patients completed the 3-week 
gluten-free diet during the first period of the study.8 Out of the 134 patients, 101 patients 
responded to a gluten-free diet and 3 patients refused randomization. In phase 2, 98 patients were 
randomized for either administration of placebo or gluten with a 7-day crossover. Inclusion 
criteria included patients greater than 16 years old and newly diagnosed with IBS based on Rome 
III criteria. Exclusion of patients with celiac disease, wheaten allergy, inflammatory bowel 
disease, psychiatric disorder, and any major comorbidities due to wanting to focus on a 
population group primarily with IBS. In phase 2 of the study, patients were divided into a control 
group (n=48) and an interventional group (n=58) where they were administered gluten 
supplements. Both groups were administered 7 gastrosoluble capsules per day. Each patient was 
administered 5.6 g of gluten content to consume. During phase 1, no adverse events were noted 
during the three-week gluten free diet course; however, during phase 2, one adverse event 
occurred during the placebo administration. Mild periorbital edema was recorded. The patients 
were also asked to report their general wellbeing using the VAS. The double-blind placebo-
controlled challenge (DBPCC) positive indicated symptoms when eating a gluten-diet and 
DBPCC negative indicated no symptoms when eating a gluten-diet (Table 3). Abdominal pain 
was 5.4 ± 2.4 for DBPCC positive and 3.2 ± 2.8 for DBPCC negative.8 Based on the results the 
RBI was -67.2%, ABI was -50.6%, and the NNT was -1 (Table 2). The negative ABI indicates 
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that there was 50.6% increase of an adverse event as a result of the gluten diet. This negative 
NNT value indicates that for every 1 participant who had a gluten containing diet, there was one 
fewer incidence of decreased IBS symptoms than in the group of participants in the placebo 
group. The p-value is 0.001 which is statistically significant.  
Table 3: Double-blind placebo-controlled challenge abdominal symptoms mean and 
standard deviation 
 
Variable DBPCC Positive DBPCC Negative P-value 
Abdominal pain 5.4 ± 2.4 3.2 ± 2.8 0.006 
Stool consistency 
satisfaction 
4.5 ± 2.9 5.7 ± 3.0 0.08 
Bloating 8.2 ± 2.8 3.6 ± 2.9 0.0001 
Postprandial 
fullness 
6.6 ± 3.0 4.9 ± 2.9 0.01 
Early satiety 6.4 ± 2.8 4.4 ± 2.9 0.03 
Epigastric pain 2.3 ± 2.3 3.0 ± 3.0 0.27 
Other 
gastrointestinal 
symptoms  
4.6 ± 4.0  3.4 ± 3.0 0.41 
 
In Shahbazkhani et al. study, 148 patients fulfilled the Rome III criteria and were enrolled 
in the study between 2011 and 2013.9 However, only 72 patients met the inclusion and exclusion 
criteria and continued with the study (Table 1). Patients included were greater than 18 years old 
and had symptoms consistent with IBS. The patients were randomly allocated into two groups: a 
placebo group (n=37) that received gluten-free supplements and the interventional group (n=35) 
that received gluten supplements. The experimental group that received gluten were given a 
packet of 100 grams containing gluten meal. The placebo group received gluten-free powder in 
the form of packets with 100 grams containing powder of gluten-free foods. Both groups 
consumed the powder for 6 weeks while on a gluten-free diet. Powder packets were to be poured 
in a cup of water containing 150 mL of warm water, consumed at breakfast and at dinner. 
Weekly follow-up assessment was used to evaluate compliance of gluten-containing diet. 
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Optimal dietary compliance was indicated if consumption of gluten was less than 100 mg/day 
and those patients (8/80) that did not comply with this policy did not continue with the study.9 In 
this trial, there were no adverse events except discomfort or abdominal pain. After the 6 weeks, 
the patients in the placebo (the gluten-free) group had more controlled abdominal symptoms then 
the gluten-containing group (p< 0.001).9 There was a change in abdominal symptoms by week 1 
listed in Table 4. The change in symptoms score was increased from 3.1 ± 2.3 to 5.1 ± 2.2 after 
having a gluten diet and was decreased from 8.4 ± 1.5 to 3.1 ± 2.3 while on a gluten-free diet 
(Table 4).9 There was also an increase in all symptoms in the gluten-containing group, most 
significantly in bloating and overall symptoms (Table 5). Based on the results in the 
Shahbazkhani et al. study, RBI was -69.3%, ABI was -58.1%, and the NNT was -1. The negative 
NNT value means that for every 1 participant who had a gluten containing diet, there was one 
fewer incidence of decreased IBS symptoms than in the group of participants in the placebo 
group. Therefore, having a gluten diet had more symptoms then a patient with a gluten-free diet. 
The p-value was <0.001 is statistically significant.  
Table 4: Mean and standard deviation at week 1  
Type of Treatment Before Use (Mean ±SD) After Use (Mean ±SD) 
Gluten 3.1 ± 2.3 5.1 ± 2.2 
Gluten-free 8.4 ± 1.5 3.1 ± 2.3 
SD= Standard Deviation 
 
Table 5: Abdominal symptoms with gluten diet vs non-gluten diet  
 Symptoms 
Study Group Overall 
symptoms 
Satisfaction with stool 
consistency 
Tiredness Nausea Bloating 
Gluten-
group 
74.3% 77.1% 60% 8.3% 74.3% 
Placebo 
(Gluten-free) 
16.2% 8.1% 8.8% 5.4% 16.2% 
 
 
Larkin, Irritable Bowel Syndrome and Gluten 10 
Discussion 
 This systematic review compares three randomized, double-blind, placebo controlled 
clinical trials. All three studies, found improvement or reduction in IBS symptoms when having 
a gluten-free diet.  
 Gluten-free diets are used for treatment in not only IBS patients, but also in celiac 
patients, other gastrointestinal issues, and personal preference in diet. The availability to 
maintain a gluten-free diet is manageable in the United States. Unfortunately, maintaining a 
gluten-free diet is not convenient for every patient especially in other countries that have limited 
availability to gluten free products. There are no contraindications to maintaining a gluten-free 
diet; however, adherence is difficult. Patients would have to avoid all foods containing wheat, 
rye, and barley. Patients would also have to avoid hydrolyzed vegetable protein or texturized 
vegetable protein due to having fillers with gluten components. Having a gluten-free diet can 
lead to deficiencies in fiber and other nutrients. Supplements may be suggested by a provider to 
decrease any nutritional deficiencies.  
 The studies that were discussed in this systematic review contained their own limitations. 
In Biesikierski et al., the study population was limited by a small final number (n=34) for sample 
size. Recruitment of patients were difficult due to the exclusion criteria of celiac disease. It is 
also questionable whether patients that had improvements from the gluten-free diet were 
undiagnosed patients with celiac disease. The first line treatment for celiac disease patients are 
avoidance of gluten; therefore, those patients would have improvements in symptoms with a 
non-gluten diet. There is the possibility that a celiac patient was included in the data. Elli et al. 
study limitations included focusing on non-celiac gluten sensitivity (NCGS) patients oppose to 
strictly IBS patients, even though the criteria were focused on Rome III criteria. Another 
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weakness in the Elli et al. study is determining if the gluten dosage was high enough to activate a 
response in the patient. Besides limitations and weaknesses found in these studies, there were 
also some limitations in researching studies due to most gluten-free diet studies focused on celiac 
disease or NCGS instead of IBS relating to gluten-free diets. 
Conclusion 
 Based on these three randomized, double-blind, placebo controlled clinical trials gluten-
free diet is effective in decreasing symptoms for IBS. All three randomized trials, found a 
statistically significant improvement in symptoms of IBS including abdominal pain, bloating, 
stool defecation, fatigue, and overall symptoms using a gluten-free diet. These studies suggest 
incorporating a gluten-free diet in patients with IBS along with other current therapies could be 
beneficial in diminishing abdominal symptoms.  
 Even though with this convincing evidence, additional research should be performed to 
determine if efficacy in gluten-free diets have more effect on patients with IBS with constipation 
verses IBS with diarrhea verses IBS mixed. Additional research can also test monotherapy of 
gluten-free diet compared to dual therapy of gluten-free diet with pharmaceutical therapies to 
determine if efficacy is increased with monotherapy verses dual therapy. Lastly, additional 
research could determine long-term effects and benefits of having a gluten-free diet.
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